Skip to content
Carboprost tromethamine
Hemabate (carboprost tromethamine) is a small molecule pharmaceutical. Carboprost tromethamine was first approved as Hemabate on 1982-01-01. It is used to treat cystitis, fetal death, incomplete abortion, and postpartum hemorrhage in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
urogenital diseasesD000091642
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Hemabate (generic drugs available since 2019-07-02)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Carboprost tromethamine
Tradename
Company
Number
Date
Products
HEMABATEMylanN-017989 RX1982-01-01
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
carboprost tromethamineANDA2023-06-20
hemabateNew Drug Application2018-01-31
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
cystitisEFO_1000025D003556N30
fetal deathHP_0003826D005313—
incomplete abortionEFO_1001799D000027—
postpartum hemorrhage—D006473O72
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
G: Genito urinary system and sex hormones
— G02: Other gynecologicals in atc
— G02A: Uterotonics
— G02AD: Prostaglandins, oxytocics
— G02AD04: Carboprost
HCPCS
No data
Clinical
Clinical Trials
6 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PresbyopiaD011305H52.4—12——3
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HeadacheD006261HP_0002315R51————22
Drug-related side effects and adverse reactionsD064420T88.7————11
CataractD002386EFO_0001059H26.9————11
Choroid diseasesD015862HP_0000610H31.9————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCARBOPROST TROMETHAMINE
INNcarboprost
Description
Carboprost is prostaglandin F2alpha in which the hydrogen at position 15 is substituted by methyl (S configuration). It is used as an abortifacient agent that is effective in both the first and second trimesters of pregnancy. It has a role as an oxytocic and an abortifacient. It is functionally related to a prostaglandin F2alpha. It is a conjugate acid of a carboprost(1-).
Classification
Small molecule
Drug classprostaglandins
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCCCC[C@](C)(O)/C=C/[C@H]1[C@H](O)C[C@H](O)[C@@H]1C/C=C\CCCC(=O)O.NC(CO)(CO)CO
Identifiers
PDB—
CAS-ID35700-23-3
RxCUI2051
ChEMBL IDCHEMBL1237105
ChEBI ID—
PubChem CID5281075
DrugBankDB00429
UNII ID7B5032XT6O (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 412 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
105 adverse events reported
View more details